PDPK1 and cancer: By contrast, their expressions were significantly associated with sensitivity of enriched anti-tumor drugs, such as PDPK1 inhibitor BX-912, Small Molecule NPK76−II−72−1, mitotic motor protein inhibitor Ispinesib, and chemotherapeutic drugs Methotrexate and 5−Fluorouracil, highlighting the potential clinical therapeutic strategies for USP45 overexpressed cancer patients.